Valuation: Mirum Pharmaceuticals, Inc.

Market Cap 5.58B 4.99B 4.64B 4.22B 7.97B 541B 8B 55.84B 21.88B 276B 20.97B 20.51B 884B P/E 2026 *
-5.69x
P/E 2027 * -123x
Enterprise Value 5.77B 5.15B 4.79B 4.36B 8.23B 558B 8.26B 57.65B 22.59B 284B 21.65B 21.18B 913B EV / Sales 2026 *
8.28x
EV / Sales 2027 * 6.91x
Free-Float
98.32%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Mirum Pharmaceuticals, Inc.

1 day+5.73%
1 week+3.71%
Current month+0.62%
1 month-12.50%
3 months-32.65%
6 months-13.08%
Current year+8.89%
1 week 77.78
Extreme 77.78
87.79
1 month 77.78
Extreme 77.78
103.28
Current year 73.82
Extreme 73.82
130
1 year 63.23
Extreme 63.232
130
3 years 23.14
Extreme 23.14
130
5 years 12.82
Extreme 12.82
130
10 years 6.51
Extreme 6.5126
130
Manager TitleAgeSince
Chief Executive Officer 47 2019-03-20
Director of Finance/CFO 66 2023-09-10
President 48 2024-01-15
Director TitleAgeSince
Chairman 73 2019-03-20
Director/Board Member 55 2018-11-06
Director/Board Member 47 2018-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
10/6/26 Exercice

Founder

24,394 0.0376%
9/14/26 Sell

Chief Financial Officer

-9,943 0.0153%
9/2/26 Sell

Controller/Auditor

-658 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
+5.73%+3.71% - - 5.28B
Average +5.73%
Weighted average by Cap. +5.73%

Financials

2026 *2027 *
Net sales 697M 622M 579M 526M 994M 67.41B 998M 6.96B 2.73B 34.37B 2.62B 2.56B 110B 820M 732M 681M 619M 1.17B 79.31B 1.17B 8.19B 3.21B 40.44B 3.08B 3.01B 130B
Net income -926M -827M -769M -700M -1.32B -89.62B -1.33B -9.26B -3.63B -45.69B -3.48B -3.4B -147B -26.73M -23.87M -22.21M -20.2M -38.14M -2.59B -38.31M -267M -105M -1.32B -100M -98.19M -4.23B
Net Debt 181M 162M 150M 137M 258M 17.51B 259M 1.81B 709M 8.93B 679M 665M 28.65B 74.95M 66.94M 62.27M 56.64M 107M 7.25B 107M 749M 294M 3.7B 281M 275M 11.87B
Projected Income Statement - Annual - Mirum Pharmaceuticals, Inc.
Logo Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States, Canada and Japan. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Employees
433
Date Price Change Volume
26-10-09 US$86.01 +5.73% 1,139,705
26-10-08 US$81.35 +0.88% 664,296
26-10-07 US$80.64 +1.75% 1,020,895
26-10-06 US$79.25 -2.68% 1,146,951
26-10-05 US$81.43 -1.81% 980,143
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Ratings Surperformance© - Mirum Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
86.01USD
Average target price
145.79USD
Spread / Average Target
+69.50%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Mirum Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. MIRM Stock